カテゴリ： GlobalData, アメリカ, 企業調査

Athenex Inc (ATNX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Athenex Inc (ATNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8003
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：89
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of paclitaxel (Oraxol), irinotecan (Oratecan), and docetaxel (Oradoxel) for the treatment of metastatic breast, colorectal, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancers. Its Src kinase product candidates comprises KX-01, a novel orally administered small molecule compound for the treatment of actinic keratosis; and KX-02 for solid tumors. Athenex offers services including drug discovery, drug formulation and clinical development, API manufacturing services. The company partners with pharmaceutical companies, universities and research institutions for the advancement and commercialization of its products. It has operations with product manufacturing facilities in the US, China, Taiwan and Hong Kong. Athenex is headquartered in Buffalo, New York, the US.

Athenex Inc (ATNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11
Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Athenex Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 14
Venture Financing 15
Athenex Raises USD20 Million in Venture Debt Financing 15
Athenex Raises USD38 Million in Financing 16
Kinex Pharma Raises USD10 Million in Venture Financing 17
Kinex Pharma Raises USD74.4 Million in Venture Financing 18
Kinex Pharma Raises US$0.3 Million In Venture Financing 19
Kinex Pharma Raises Funds In First Tranche Of Financing Round 20
Kinex Pharma Raises US$5 Million In Venture Financing 21
Private Equity 22
Athenex to Raise USD50 Million in Equity Financing 22
Partnerships 23
Athenex to Form Joint Venture with Xiangxue Life Sciences 23
Athenex Forms Joint Venture with SunGen Pharma 24
Athenex Enters into Agreement with Imuna Pharm 25
Athenex Enters into Partnership with Eli Lilly and Company 26
Athenex Enters into Agreement with Fort Schuyler Management 27
Licensing Agreements 28
Athenex Enters into Licensing Agreement with Avalon PolyTom 28
Almirall to Enter into Licensing Agreement with Athenex for KX2-391 30
Athenex to Enter into Licensing Agreement with Gland Pharma 31
Athenex to Enter into Licensing Agreement with Gland Pharma 32
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 33
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 34
Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 35
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 37
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 39
Equity Offering 41
Athenex Completes Partial Exercise of Over-Allotment Option of Public Offering of Shares for USD72.7 Million 41
Athenex Raises USD76 Million in IPO 43
Athenex Raises USD3.5 Million in Private Placement of Shares 45
Athenex Raises USD5 Million in Private Placement of Shares 46
Athenex Raises USD6.6 Million in Private Placement of Shares 47
Kinex Pharma Raises Funds through Private Placement of Shares 48
Athenex Raises USD4 Million in Private Placement of Shares 49
Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 50
Kinex Pharma Completes Private Placement Of Shares For US$40 Million 51
Acquisition 52
Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 52
Athenex Acquires Polymed Therapeutics 53
Kinex Pharma Acquires QuaDPharma for USD5.5 Million 54
Athenex Inc – Key Competitors 55
Athenex Inc – Key Employees 56
Athenex Inc – Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Joint Venture 59
Recent Developments 60
Financial Announcements 60
Aug 14, 2018: Athenex reports second quarter 2018 financial results 60
May 14, 2018: Athenex Announces First Quarter 2018 Results 63
Mar 26, 2018: Athenex Announces Fourth Quarter and Full-Year 2017 Results 65
Nov 09, 2017: Athenex Announces Third Quarter 2017 Results 67
Aug 14, 2017: Athenex Announces Second Quarter 2017 Results 70
Corporate Communications 73
Aug 20, 2018: Athenex names Randoll Sze as Chief Financial Officer 73
Jul 09, 2018: Athenex Appoints Timothy Cook As Senior Vice President Of Global Commercial Oncology 74
Jun 15, 2018: Athenex Appoints Benson Tsang As Board Director 75
Apr 30, 2018: Athenex Announces Transition of James Zukin from Board of Directors to Advisory Role 76
Dec 01, 2017: Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle 77
Mar 01, 2017: Athenex announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer 78
Feb 27, 2017: Athenex appoints veteran J. Nick Riehle as Chief Financial Officer 79
Government and Public Interest 80
Sep 11, 2017: Athenex Announces Grant Disbursement Agreement with New York State for Dunkirk Facility 80
Product News 81
Oct 15, 2018: Athenex and Xiangxue Life Sciences announce preliminary results of patients receiving T-Cell receptor affinity enhancing specific T-Cell therapy (TAEST) showed encouraging positive clinical signals 81
Aug 10, 2017: Athenex Pharma Solutions, an Athenex, Company, Launches Three New Sterile Injectable Products from its 503(B) Facility 82
Aug 01, 2017: Athenex Announces Recent Product Launches in Commercial Business 83
Clinical Trials 84
Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting 84
Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis 85
Other Significant Developments 86
Jul 18, 2018: PolyU – axis therapeutics joint center for immunotherapy launched to develop innovative cancer treatments 86
Jul 02, 2018: Athenex forms new alliances in Asia to expand oncology pipeline 87
Feb 13, 2018: Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89

List of Tables
Athenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Athenex Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11
Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 14
Athenex Raises USD20 Million in Venture Debt Financing 15
Athenex Raises USD38 Million in Financing 16
Kinex Pharma Raises USD10 Million in Venture Financing 17
Kinex Pharma Raises USD74.4 Million in Venture Financing 18
Kinex Pharma Raises US$0.3 Million In Venture Financing 19
Kinex Pharma Raises Funds In First Tranche Of Financing Round 20
Kinex Pharma Raises US$5 Million In Venture Financing 21
Athenex to Raise USD50 Million in Equity Financing 22
Athenex to Form Joint Venture with Xiangxue Life Sciences 23
Athenex Forms Joint Venture with SunGen Pharma 24
Athenex Enters into Agreement with Imuna Pharm 25
Athenex Enters into Partnership with Eli Lilly and Company 26
Athenex Enters into Agreement with Fort Schuyler Management 27
Athenex Enters into Licensing Agreement with Avalon PolyTom 28
Almirall to Enter into Licensing Agreement with Athenex for KX2-391 30
Athenex to Enter into Licensing Agreement with Gland Pharma 31
Athenex to Enter into Licensing Agreement with Gland Pharma 32
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 33
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 34
Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 35
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 37
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 39
Athenex Completes Partial Exercise of Over-Allotment Option of Public Offering of Shares for USD72.7 Million 41
Athenex Raises USD76 Million in IPO 43
Athenex Raises USD3.5 Million in Private Placement of Shares 45
Athenex Raises USD5 Million in Private Placement of Shares 46
Athenex Raises USD6.6 Million in Private Placement of Shares 47
Kinex Pharma Raises Funds through Private Placement of Shares 48
Athenex Raises USD4 Million in Private Placement of Shares 49
Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 50
Kinex Pharma Completes Private Placement Of Shares For US$40 Million 51
Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 52
Athenex Acquires Polymed Therapeutics 53
Kinex Pharma Acquires QuaDPharma for USD5.5 Million 54
Athenex Inc, Key Competitors 55
Athenex Inc, Key Employees 56
Athenex Inc, Subsidiaries 58
Athenex Inc, Joint Venture 59

List of Figures
Athenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Athenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Athenex Inc (ATNX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Senetas Corporation Limited：企業の戦略・SWOT・財務分析
    Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Mississippi Power Co：企業の戦略的SWOT分析
    Mississippi Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Interventional Spine, Inc.-医療機器分野：企業M&A・提携分析
    Summary Interventional Spine, Inc. (Interventional Spine) is a medical device company, which designs, develops and markets patented systems to treat back pain. The company’s major products include PerX360° percutaneous lumbar fusion system, PERPOS PLS percutaneous transfacet-pedicular compression sy …
  • Bollore SA (BOL)：企業の財務・戦略的SWOT分析
    Bollore SA (BOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Encavis AG：企業のM&A・事業提携・投資動向
    Encavis AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Encavis AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Exide Technologies：企業の戦略・SWOT・財務分析
    Exide Technologies - Strategy, SWOT and Corporate Finance Report Summary Exide Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Balfour Beatty plc：企業の戦略・SWOT・財務情報
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Companhia Energetica de Sao Paulo (CESP6)：企業の財務・戦略的SWOT分析
    Companhia Energetica de Sao Paulo (CESP6) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Gemphire Therapeutics Inc (GEMP)：製薬・医療：M&Aディール及び事業提携情報
    Summary Gemphire Therapeutics Inc (Gemphire), formerly Michigan Life Therapeutics LLC, is a clinical stage biopharmaceutical company that develops and commercializes therapies for patients with cardiometabolic disorders, including dyslipidemia and non-alcoholic steatohepatitis (NASH). Its lead produ …
  • Fagron NV (FAGR)：企業の財務・戦略的SWOT分析
    Summary Fagron NV (Fagron), formerly Arseus NV is a pharmaceutical compounding solution provider. The company offers products such as raw materials, extracts and tinctures, flammable products, anesthesia, ointment bases, syrups, suspension media, triturations, phyto pharmaflore, medispend, capsicard …
  • RayBiotech Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary RayBiotech Inc (RayBiotech) is a life science company that provides proteins, antibodies and immunological kits. The company's product categories include antibody arrays, glycobiology arrays, protein arrays, phosphorylation arrays, elisa, functional assays, antibodies and custom recombinant …
  • One Medical Group Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary One Medical Group Inc (One Medical) is a provider of medical and technology-enabled health care services. The company’s service offerings include primary and pediatric care, prenatal and women's health, nutrition and sports medicine, LGBT care, mental health, dermatology, family and integrat …
  • 84 Lumber Company：企業の戦略・SWOT・財務分析
    84 Lumber Company - Strategy, SWOT and Corporate Finance Report Summary 84 Lumber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Landesbank Berlin Holding Ag
    Landesbank Berlin Holding Ag - Strategy, SWOT and Corporate Finance Report Summary Landesbank Berlin Holding Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • NCC Group plc：企業の戦略・SWOT・財務分析
    NCC Group plc - Strategy, SWOT and Corporate Finance Report Summary NCC Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • UTair Aviation：企業の戦略・SWOT・財務情報
    UTair Aviation - Strategy, SWOT and Corporate Finance Report Summary UTair Aviation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Ferrovial, S.A. (FER)：企業の財務・戦略的SWOT分析
    Ferrovial, S.A. (FER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Neurocrine Biosciences Inc (NBIX)：企業の財務・戦略的SWOT分析
    Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • OpGen Inc (OPGN)：製品パイプライン分析
    Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, s …
  • Natus Medical Incorporated (BABY)-医療機器分野：企業M&A・提携分析
    Summary Natus Medical Incorporated (Natus) is a provider of newborn and neurology healthcare products. Its offers wide range of products for the screening, diagnosis, detection, treatment, monitoring and tracking of ailments in newborn. Natus also offers products for diagnostic hearing assessment in …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆